Key result
Depletion of endogenous DDX42 increased HIV-1, CHIKV, and SARS-CoV-2 infection in cell lines and primary cells, while its overexpression inhibited infection, identifying DDX42 as an intrinsic antiviral inhibitor.
Why the study?
Does DDX42 depletion or overexpression alter the infection efficiency of positive-strand RNA viruses in cell models?
Does DDX42 depletion or overexpression alter the infection efficiency of positive-strand RNA viruses in cell models?
This is the authors' abstract. We don't add key points for this paper.
Genome‐wide screens are powerful approaches to unravel regulators of viral infections. Here, a CRISPR screen identifies the RNA helicase DDX42 as an intrinsic antiviral inhibitor of HIV‐1. Depletion of endogenous DDX42 increases HIV‐1 DNA accumulation and infection in cell lines and primary cells. DDX42 overexpression inhibits HIV‐1 infection, whereas expression of a dominant‐negative mutant increases infection. Importantly, DDX42 also restricts LINE‐1 retrotransposition and infection with other retroviruses and positive‐strand RNA viruses, including CHIKV and SARS‐CoV‐2. However, DDX42 does not impact the replication of several negative‐strand RNA viruses, arguing against an unspecific effect on target cells, which is confirmed by RNA‐seq analysis. Proximity ligation assays show DDX42 in the vicinity of viral elements, and cross‐linking RNA immunoprecipitation confirms a specific interaction of DDX42 with RNAs from sensitive viruses. Moreover, recombinant DDX42 inhibits HIV‐1 reverse transcription in vitro. Together, our data strongly suggest a direct mode of action of DDX42 on viral ribonucleoprotein complexes. Our results identify DDX42 as an intrinsic viral inhibitor, opening new perspectives to target the life cycle of numerous RNA viruses. A CRISPR screen identifies the helicase DDX42 as an intrinsic inhibitor of HIV‐1. DDX42 also inhibits replication of various positive‐strand viruses, with a strong impact on coronaviruses, possibly through binding viral RNAs. A CRISPR screen identifies the helicase DDX42 as an intrinsic inhibitor of HIV‐1. DDX42 also inhibits replication of various positive‐strand viruses, with a strong impact on coronaviruses, possibly through binding viral RNAs.
Answers are grounded in this paper and cite their sources.
DDX42 acts as an intrinsic antiviral inhibitor of HIV-1 and other positive-strand RNA viruses, potentially by directly interacting with viral ribonucleoprotein complexes.
No takes yet. Share an insight, caveat, or question.
Bonaventure et al. (2022) studied HIV-1 and other positive-strand RNA virus infections. DDX42 depletion or overexpression vs. Control cells (non-targeting sgRNA, control siRNA, or Firefly expression) was evaluated on Viral infection efficiency and viral DNA accumulation. Depletion of endogenous DDX42 increased HIV-1, CHIKV, and SARS-CoV-2 infection in cell lines and primary cells, while its overexpression inhibited infection, identifying DDX42 as an intrinsic antiviral inhibitor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: